Articles by Jeffrey S. Buguliskis, PhD

  1. Six Specialized Modalities Testing CDMO Readiness In 2026 2/27/2026

    As biopharma pipelines shift toward more complex therapies, sponsors are finding that CDMO readiness now depends less on general capacity and more on highly specific technical capabilities.

  2. End-To-End ADC Manufacturing Works Best With Active Sponsor Oversight 2/6/2026

    ADC success is less about perfect execution and more about early signal detection, tight communication, and decisive governance.

  3. 7 Outsourcing Behaviors for 2026 That Will Protect Timelines 12/29/2025

    Protecting manufacturing timelines in 2026 means converting speed from a hope into a contractual commitment through strategic prepayment, integrated partnerships, and formalized accountability.

  4. The Top 10 Nations Redrawing The Outsourcing Map 12/8/2025

    There was a time when your outsourcing strategy could be managed with a simple spreadsheet and a focus on cost-per-liter. Those days are gone…

  5. How AI Is Rewriting Tech Transfer Timelines 11/26/2025

    By replacing trial-and-error with virtual simulations and predictive analytics, AI is giving even small biotechs the process development capabilities once reserved for Big Pharma—and slashing tech transfer timelines in the process.

  6. The 9 Fastest-Growing Outsourcing Segments 10/21/2025

    Capacity isn’t the choke point—capability is; this piece ranks nine fast-growing outsourcing segments and shows sponsors how to win by locking in modality-proven partners early.

  7. Cell & Gene Therapy Outsourcing's New Paradigm 10/7/2025

    The industry has flipped from scarcity to surplus, and sponsors now have leverage to set terms, not take numbers.

  8. Clear The Outsourcing Runway: The 8 Largest Deals In The Past Year 9/30/2025

    We ranked the past year’s eight biggest pharma–CDMO manufacturing deals and decoded what they signal for your next outsourcing project.

  9. Green Is The New KPI: Sustainability In Pharma Outsourcing 9/10/2025

    Sustainability is moving from marketing to metering, as sponsors look for facility-level metrics and contract incentives that drive measurable improvement.